These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 3413082)

  • 1. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.
    Garcia DL; Anderson S; Rennke HG; Brenner BM
    Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6142-6. PubMed ID: 3413082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.
    Roth D; Smith RD; Schulman G; Steinman TI; Hatch FE; Rudnick MR; Sloand JA; Freedman BI; Williams WW; Shadur CA
    Am J Kidney Dis; 1994 Nov; 24(5):777-84. PubMed ID: 7977319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation.
    Garcia DL; Rennke HG; Brenner BM; Anderson S
    J Clin Invest; 1987 Sep; 80(3):867-74. PubMed ID: 3040810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J; Koch KM
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoids amplify glomerular injury in rats with renal ablation.
    García DL; Rennke HG; Brenner BM; Anderson S
    Am J Hypertens; 1988 Jan; 1(1):54-7. PubMed ID: 3370134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension.
    Lafferty HM; Garcia DL; Rennke HG; Troy JL; Anderson S; Brenner BM
    J Am Soc Nephrol; 1991 Apr; 1(10):1180-5. PubMed ID: 1768813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
    Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi-institutional study in Japan.
    Akizawa T; Koshikawa S; Takaku F; Urabe A; Akiyama N; Mimura N; Otsubo O; Nihei H; Suzuki Y; Kawaguchi Y
    Int J Artif Organs; 1988 Sep; 11(5):343-50. PubMed ID: 3056862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin.
    Schaefer RM; Leschke M; Strauer BE; Heidland A
    Am J Nephrol; 1988; 8(6):449-53. PubMed ID: 3218658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
    Anderson S; Meyer TW; Rennke HG; Brenner BM
    J Clin Invest; 1985 Aug; 76(2):612-9. PubMed ID: 2993362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury.
    Tolins JP; Raij L
    Hypertension; 1990 Oct; 16(4):452-61. PubMed ID: 2210813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of erythropoietin induced hypertension in a bilaterally nephrectomized patient.
    Sasaki N; Ando Y; Kusano E; Asano Y
    ASAIO J; 2003; 49(1):131-5. PubMed ID: 12558321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of purified recombinant human erythropoietin on anemia in rats with experimental renal failure induced by five-sixth nephrectomy.
    Kawamura A; Higuchi M; Imai N; Kawaguchi T; Ogura Y
    Biotherapy; 1990; 2(1):77-85. PubMed ID: 2400629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial.
    Kleinman KS; Schweitzer SU; Perdue ST; Bleifer KH; Abels RI
    Am J Kidney Dis; 1989 Dec; 14(6):486-95. PubMed ID: 2688405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for recombinant human erythropoietin therapy.
    Eschbach JW; Adamson JW
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who should receive recombinant human erythropoietin?
    Van Stone JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.